Rossby Financial LCC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Rossby Financial LCC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,511 shares of the biopharmaceutical company's stock, valued at approximately $232,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust purchased a new position in Gilead Sciences in the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC lifted its position in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the company's stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the sale, the chief financial officer now owns 171,223 shares of the company's stock, valued at $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 302,785 shares of company stock worth $30,540,875. Company insiders own 0.16% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

GILD has been the topic of several recent research reports. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Bank of America upped their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Morgan Stanley upped their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, March 11th. Finally, DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research report on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Price Performance

GILD stock traded down $0.80 on Wednesday, hitting $104.88. 7,115,838 shares of the company's stock traded hands, compared to its average volume of 7,504,431. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The stock has a market cap of $130.59 billion, a price-to-earnings ratio of 283.46, a P/E/G ratio of 0.71 and a beta of 0.32. The stock has a fifty day moving average of $108.63 and a 200-day moving average of $97.11.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.01%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences's dividend payout ratio is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.